Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06386744 | Dusquetide for the Treatment of Behcet's Disease | PHASE2 | COMPLETED | 8 | — | — | Nov 18, 2024 | Jun 17, 2025 | Aug 1, 2025 | 1 | Turkey (Türkiye) |
The number of oral ulcers will be counted at baseline and each visit during the treatment period.
The number of genital ulcers will be counted at baseline and each visit during the treatment period.
| Arm | Type | Description |
|---|---|---|
| SGX945 | EXPERIMENTAL | This is an open-label study and all participants will receive SGX945. |
| Name | Type | Description |
|---|---|---|
| Dusquetide | DRUG | 1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks |
Inclusion Criteria: * Participants must have a clinical diagnosis of Behcet's Disease meeting the International Study Group criteria. * Participants must have at least two oral ulcers and/or one genital ulcer on the day of randomization. * Participants willing to follow the clinical protocol and vo...